Aether Pacific Pharmaceuticals, formerly Medical Kiwi. New Website Coming Soon.

Medical Kiwi

Uptake agreement with UK distributor Liberty Herbal Technologies secures future sales

Precision medicinal cannabis inhaler technology is on its way to New Zealand after Medical Kiwi signed an exclusive uptake agreement with UK distributor Liberty Herbal Technologies Ltd.

The uptake agreement is another significant step forward for Medical Kiwi as they build their global network of clients and strategic partners. Medical Kiwi will supply dried medical cannabis to Liberty Herbal Technologies to be packaged and sold internationally for use with Liberty’s patented technology, the unique hapac device, from early 2021. In addition, Medical Kiwi will have exclusive rights to import the hapac product for sale in New Zealand from early 2020.

Medical Kiwi Chairman, Aldo Miccio, says securing future sales in uptake agreements help to plan the production facilities with certainty. “The memorandum of understanding allows for Medical Kiwi to provide our unique IP raw materials to Liberty Herbal Technologies for wider distribution globally. This means we have the perfect strategic alliance to aid us in achieving both company’s visions,” says Aldo.
Introduced earlier this year in London, Medical Kiwi and Liberty Herbal Technologies are both innovative, emerging businesses. “Liberty Herbal Technologies share the same purpose as Medical Kiwi. Our innovative technology, hapac – the new measured-dose inhalable system – combined with Medical Kiwi’s high-quality cannabis strain and formulation will enable patients to have access to reduced risk, effective, affordable, high-quality medicinal cannabis products. We are looking forward to starting our collaboration and bringing this unique combination to Europe and New Zealand,” says Domenico Ventura, Liberty Herbal Technology Founder, CEO and Marketing Director.

Hapac (herb and paper anti combustion) is a precision medicinal cannabis dry-vaping inhaler system. In comparison to existing inhalation methods, there is no combustion, and no smoke. The device’s “heat-not-burn” technology means the medicinal cannabis is vaporised at 210 degrees Celsius rather than combustion that occurs at 885 degrees Celsius. The device works with ready-to-use, pre-ground medicinal cannabis packaged in measured doses in sachets made from natural materials (pure cellulose, derived from wood pulp), so after they’ve been used, they can be safely composted.

“The technology in their innovative device is a great match for our strategic goal to bring to market in New Zealand the best delivery mechanisms for medicinal cannabis,” says Aldo. “Obtaining cutting edge medical technology for our exclusive use in New Zealand helps ensure we are not only leaders in the medical cannabis industry in New Zealand, but also globally.”